SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): June 10, 2004
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
- -------- ------- ----------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On June 10, 2004, the Registrant disseminated a Press Release
announcing that it will provide a live webcast of its corporate
presentation at the Needham & Company Third Annual Biotechnology
Conference on Thursday, June 17, 2004, at the New York Palace Hotel.
The presentation will be given at 9:30 a.m. (ET) by Harvey J.
Berger, M.D., chairman and chief executive officer of ARIAD, who will
provide an overview of the Company and its progress in key programs.
The information contained in the Press Release dated June 10, 2004,
is incorporated herein by reference and attached as Exhibit 99.1
hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 10, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: June 10, 2004
2
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- ----------------------
99.1 The Registrant's Press Release 4
dated June 10, 2004.
3